Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are markers of systemic inflammation associated with poor outcome in several solid tumours. We retrospectively investigated the prognostic role of PLR and, secondly, NLR in mCRPC patients treated with Abiraterone Acetate (AA) or Enzalutamide (E), both in pre- and post-docetaxel setting.
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide
Pisano, ChiaraFirst
;DI Stefano, Rosario F;Turco, Fabio;Samuelly, Alessandro;Bungaro, Maristella;Scagliotti, Giorgio V;DI Maio, Massimo;Buttigliero, ConsueloLast
2021-01-01
Abstract
Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are markers of systemic inflammation associated with poor outcome in several solid tumours. We retrospectively investigated the prognostic role of PLR and, secondly, NLR in mCRPC patients treated with Abiraterone Acetate (AA) or Enzalutamide (E), both in pre- and post-docetaxel setting.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PLR_Paper_CP_25-06-20 preprint.docx
Accesso riservato
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
58.9 kB
Formato
Microsoft Word XML
|
58.9 kB | Microsoft Word XML | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
